INFLUENCE OF TOPICAL RETAPAMULIN (1%) OINTMENT, SOFINOX- RD CREAM, SOFINOX CREAM (2%), ZINC FUSIDATE CREAM (2%) AND ZINC FUSIDATE OINTMENT (2%) ON NASAL MUCOSAL SURFACE SAFETY IN NEW ZEALAND ALBINO RABBITS
Keywords:
Nasal safety, Retapamulin, Zinc fusidate, SofinoxAbstract
Objective: To investigate the comparative safety of Retapamulin 1% ointment, Sodium fusidate 0.25%, Sofinox 2% cream, Zinc fusidate 2% cream and Zinc fusidate 2% ointment on nasal mucosal surface in rabbits.
Methods: In the experiment a total of 30 adult New Zealand albino rabbits of either sex were used. The rabbits were divided into five groups of six rabbits each. A thin layer of the drug was applied in the right nostril and left nostril was kept as control (no treatment) to their corresponding treatment group. Nasal safety of these drugs was assessed with the help of a symptom scoring system and photographic observations.
Results: There was significant decrease of nasal rubbing (Rhinocnesmus) behaviors in experimental animals of Sofinox RD cream (p<0.001), Sofinox 2% cream (p<0.001), Zinc fusidate cream (p<0.001) and Zinc fusidate ointment (p<0.001) treated groups when compared with Retapamulin 1% ointment treated group. More redness was observed in nasal mucosal surface of both nostrils (Right nostril- Retapamulin 1% ointment, Left nostril- Control) of Retapamulin group animals in comparison with Sofinox RD cream, Sofinox 2% cream, Zinc fusidate 2% cream and Zinc fusidate 2% ointment group animals.
Conclusion: In the present study, the comparative safety of test drugs on nasal mucosal surface of rabbits were found as- Zinc fusidate ointment > Zinc fusidate cream > Sofinox RD cream ~ Sofinox 2% cream > Retapamulin 1% ointment. Further, clinical evaluation has to be performed to precisely define the safety of Zinc fusidate ointment, Zinc fusidate cream, Sofinox RD cream and Sofinox 2% cream on nasal mucosal surface of human subjects.
Â
Downloads
References
Melo Naves M, Gomes Patrocinio L, Patrocinio JA, Naves Mota FM, Diniz de Souza A, Negrão Fleury R, et al. Contribution of nasal biopsy to leprosy diagnosis. Am J Rhinol Allergy 2009;23:177e80.
Kluytmans J, Belkum AV, Verbrugh H. Nasal carriage of staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10(3):505–20.
Williams REO. Healthy carriage of Staphylococcus aureus: its prevalence and importance. Bacteriol Rev 1963;27:56–71.
Parras F, Guerrero MC, Bouza E, Blaazquez MJS, Moreno M, Cruz M, et al. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995;39:175–9.
Reagan DR, Doebbeling BN, Pfaller MA, Sheetz CT, Houston AK, Hollis RJ, et al. Elimination of coincident S. aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Int Med 1991;114:101–6.
Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents 1999;12 Suppl 2:S59-66.
Free A, Roth E, Dalessandro M, Hiram J, Scangarella N, Shawar R, et al. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. Skin Med 2006;5(5):224-32.
Yang LP, Keam SJ. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 2008;68(6):855-73.
Parish LC, Jorizzo JL, Breton JJ, Hirman JW, Scangarella NE, Shawar RM, et al. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J Am Acad Dermatol 2006;55(6):1003-13.
Tomayko JF, Li G, Breton JJ, Scangarella ON, Dalessandro M, Martin M. The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: a randomized, double-blind superiority study. Adv Skin Wound Care 2013;26(3):113-21.
Templer SJ, Brito MO. Bacterial skin and soft tissue infections. Hospital Physician 2009;26:9-16.
Vincent Ki, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol 2008;19(2):173-84.
Pangilinan R, Tice A, Tillotson G. Topical antibiotic treatment for uncomplicated skin and skin structure infections: review of the literature. Expert Rev Anti Infect Ther 2009;7(8):957-65.
Czaja W, Krystynowicza A, Bieleckia S, Brown RM. Microbial cellulose-the natural power to heal wounds. Biomaterial 2006;27:145–51.
Satish MC, Adiga S, D’Souza A, Nayak V, Bharti Chogtu B, Bairy KL. Effect of betamethasone valerate with biopolymer on skin inflammatory models in albino mice and wistar rats. Int J Pharm Sci Rev Res 2010;4(2):173-5.